Stosowanie oklacytynibu u kotów – co już wiemy?

Piśmiennictwo

Mueller R.S., Nuttall T., Prost C., Schulz B., Bizikova P.: Treatment of the feline atopic syndrome – a systematic review. „Vet Dermatol”, 2021, 32, 43-e8. DOI: https://doi.org/10.1111/vde.12933.Older C.E., Diesel A.B., Heseltine J.C., Friedeck A., Hedke C., Pardike S., Breitreiter K., Rossi M.A., Messamore J., Bammert G., Gonzales A.J., Rodrigues Hoffmann A.: Cytokine expression in feline allergic dermatitis and feline asthma. „Vet Dermatol”, 2021, 32, 613-e163. DOI: https://doi.org/10.1111/vde.13022.Ortalda C., Noli C., Colombo S., Borio S.: Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats. „Vet Dermatol”, 2015, 26, 235-e52. DOI: https://doi.org/10.1111/vde.12218.Carrasco I., Martínez M., Albinyana G.: Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus. „Vet Dermatol”, 2021, 32, 299-301. DOI: https://doi.org/10.1111/vde.12949.Lopes N.L., Campos D.R., Machado M.A. et al.: A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats. ”BMC Vet Res”, 2019, 15, 137. DOI: https://doi.org/10.1186/s12917-019-1893-x.Isaac C., Ferrer L., Puigdemont A.: Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response. „Journal of Feline Medicine and Surgery”, 2022, 24, 8, 787-93. DOI: https://doi.org/10.1177/1098612X211048458.Moore A., Burrows A.K., Malik R., Ghubash R.M., Last R.D., Remaj B.: Fatal disseminated toxoplasmosis in a feline immunodeficiency virus-positive cat receiving oclacitinib for feline atopic skin syndrome. ”Vet Dermatol”, 2022, 33, 435-439. DOI: https://doi.org/10.1111/vde.13097.Abstracts of the North American Veterinary Dermatology Forum 15-18 April 2015 Nashville, TN, USA. „Vet Dermatol”, 2015, 26, 133-159. DOI: https://doi.org/10.1111/vde.12213.Earl Loft K., Brooke S.: Feline idiopathic ulcerative dermatosis treated successfully w...